Skip to Main Content
Try STAT+ TODAY
Trending:
Health
Biotech
STAT+
Pharma
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Acadia Pharmaceuticals buys pain drug maker, part of effort to expand on psychosis treatment

  • Matthew Herper

By Matthew Herper Aug. 25, 2020

Reprints
Hydroxychloroquine on tray
GEORGE FREY/AFP via Getty Images

Acadia Pharmaceuticals is purchasing a small Texas startup, CerSci, for $52 million in order to acquire a pain drug in the early stages of development, the company said Tuesday.

If the drug succeeds, CerSci could receive an additional $887 million in payments for hitting commercial and development milestones.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Matthew Herper

Matthew Herper

Senior Writer, Medicine, Editorial Director of Events

Matthew Herper covers medical innovation — both its promise and its perils.

Tags

Eye drops linked to U.S. drug-resistant bacteria outbreak
Eye drops linked to U.S. drug-resistant bacteria outbreak
Medicare Advantage insurers to repay billions under final federal…
Medicare Advantage insurers to repay billions under final federal audit rule
New research casts fresh doubt on a common procedure…
New research casts fresh doubt on a common procedure that promises to increase the odds of…
Listen: Pharma blockbusters, pandemic policy, & legal chicanery
Listen: Pharma blockbusters, pandemic policy, & legal chicanery
Pharmalittle: GSK CEO warns U.K. pharma industry is at…
Pharmalittle: GSK CEO warns U.K. pharma industry is at a ‘tipping point’; Gavi tussles with vaccine…
Biden administration floats major 2024 pay cut for Medicare…
Biden administration floats major 2024 pay cut for Medicare Advantage plans

Recommended Stories